Age-related changes in bone formation, osteoblastic cell proliferation, and differentiation during postnatal osteogenesis in human calvaria.
We have determined the age-related changes in the growth characteristics and expression of the osteoblast phenotype in human calvaria osteoblastic cells in relation with histologic indices of bone formation during postnatal calvaria osteogenesis. Histomorphometric analysis of normal calvaria samples obtained from 36 children, aged 3 to 18 months, showed an age-related decrease in the extent of bone surface covered with osteoblasts and newly synthesized collagen, demonstrating a progressive decline in bone formation during postnatal calvaria osteogenesis. Immunohistochemical analysis showed expression of type I collagen, bone sialoprotein, and osteonectin in the matrix and osteoblasts, with no apparent age-related change during postnatal calvaria osteogenesis. Cells isolated from human calvaria displayed characteristics of the osteoblast phenotype including alkaline phosphatase (ALP) activity, osteocalcin (OC) production, expression of bone matrix proteins, and responsiveness to calciotropic hormones. The growth of human calvaria osteoblastic cells was high at 3 months of age and decreased with age, as assessed by (3H)-thymidine incorporation into DNA. Thus, the age-related decrease in bone formation is associated with a decline in osteoblastic cell proliferation during human calvaria osteogenesis. In contrast, ALP activity and OC production increased with age in basal conditions and in response to 1,25(OH)2 vitamin D3, suggesting a reciprocal relationship between cell growth and expression of phenotypic markers during human postnatal osteogenesis. Finally, we found that human calvaria osteoblastic cells isolated from young individuals with high bone formation activity in vivo and high growth potential in vitro had the ability to form calcified nodular bone-like structures in vitro in the presence of ascorbic acid and beta-glycerophosphate, providing a new model to study human osteogenesis in vitro.
de Pollak
C
C
INSERM Unité 349, Lariboisière Hospital, Paris, France.
Arnaud
E
E
Renier
D
D
Marie
P J
PJ
D000367:Age Factors; D000469:Alkaline Phosphatase / Q000187:drug effects / Q000378:metabolism; D001205:Ascorbic Acid / Q000494:pharmacology; D001846:Bone Development / Q000502:physiology*; D002117:Calcitriol / Q000494:pharmacology; D002454:Cell Differentiation; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D003094:Collagen / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D058574:Integrin-Binding Sialoprotein; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D015675:Osteocalcin / Q000096:biosynthesis / Q000187:drug effects; D010012:Osteogenesis / Q000502:physiology*; D015676:Osteonectin / Q000378:metabolism; D010641:Phenotype; D012795:Sialoglycoproteins / Q000378:metabolism; D012886:Skull / Q000166:cytology* / Q000254:growth & development*
C546871:IBSP protein, human; D058574:Integrin-Binding Sialoprotein; D015676:Osteonectin; D012795:Sialoglycoproteins; D015675:Osteocalcin; D003094:Collagen; D000469:Alkaline Phosphatase; D002117:Calcitriol; D001205:Ascorbic Acid